Novavax (NVAX) Stock Falls Again: Is It a Better Investment Now?

The Novavax Inc (NASDAQ:NVAX) stock has slumped this morning after a report in a leading newspaper suggested that the company is unlikely to apply for the emergency use authorization for its COVID 19 vaccine until June this year.

Novavax (NVAX) Stock Falls Again: Is It a Better Investment Now?

That is a considerable delay and the report has naturally resulted in a certain degree of panic among investors. The report stated that Novavax is not going to release the results from the study of its vaccine up until the end of May.

Related:  MultiCell (MCET) Gains Over 23% On High Volume: But Why?

That is going to be a week later than many on Wall Street were expecting. This has resulted in a quick selloff in the stock this morning and it has declined by 6% at the time of writing.

Novavax has been one of the more popular stocks among investors looking for coronavirus plays and since the beginning of 2020, it has delivered gains of a staggering 4000%. It will be interesting to see if the company comes up with a statement today or not.

Uson Abdilazhanov

Editor and Computer Expert A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.